Endometriosis is characterized by the growth of endometrial-like tissue outside the uterus, and it is associated with alterations in the expression of hormone receptors and inflammation. Estetrol (E
4) is a weak estrogen that recently has been approved for contraception. We evaluated
[...] Read more.
Endometriosis is characterized by the growth of endometrial-like tissue outside the uterus, and it is associated with alterations in the expression of hormone receptors and inflammation. Estetrol (E
4) is a weak estrogen that recently has been approved for contraception. We evaluated the effect of E
4 on the growth of endometriotic-like lesions and the expression of TNF-α, estrogen receptors (ERs), and progesterone receptors (PRs) in an in vivo murine model. Endometriosis was induced surgically in female C57BL/6 mice. E
4 was delivered via Alzet pump (3 mg/kg/day) from the 15th postoperative day for 4 weeks. E
4 significantly reduced the volume (
p < 0.001) and weight (
p < 0.05) of ectopic lesions. Histologically, E
4 did not affect cell proliferation (PCNA immunohistochemistry) but it did increase cell apoptosis (TUNEL assay) (
p < 0.05). Furthermore, it modulated oxidative stress (SOD, CAT, and GPX activity,
p < 0.05) and increased lipid peroxidation (TBARS/MDA,
p < 0.01). Molecular analysis showed mRNA (RT-qPCR) and protein (ELISA) expression of TNF-α decreased (
p < 0.05) and mRNA expression of
Esr2 reduced (
p < 0.05), in contrast with the increased expression of
Esr1 (
p < 0.01) and
Pgr (
p < 0.05). The present study demonstrates for the first time that E
4 limited the development and progression of endometriosis in vivo.
Full article